New Era of Targeted Therapies for Rare Skeletal Diseases - Hypophosphatasia: Bone-Targeted Enzyme Replacement With Asfotase Alfa
Michael Whyte, MD
Washington University School of Medicine
Please complete the form here or contact licensing@endocrine.org to learn more about licensing content from the Endocrine Society.
If you believe you should have access to this media, please login.
